PAS-003


Associated tags: DSM-IV codes, Amyotrophy, Survival, National academy, Pharmaceutical industry, Central nervous system, Patient, ALS, Research, CNS, Integrin, SOD1, KTTA, Behavior, PNAS, Pasithea (Charites), Clinical professor, Mayo Clinic, Multiple sclerosis, Stanford University, HIV disease progression rates, Oregon Health & Science University

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Retrieved on: 
Thursday, November 9, 2023
Survival, PNAS, IND, Stanford University, Patent, SOD1, KTTA, Clinical professor, Behavior, National academy, CNS, Natalizumab, Research, HIV disease progression rates, FN, Oregon Health & Science University, Disease, ALS, Multiple sclerosis, Integrin, Patient, Mayo Clinic, MS, SAN, Central nervous system, Pharmaceutical industry, Pasithea (Charites), Nature

SOUTH SAN FRANCISCO, Calif. and MIAMI, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, announced today that it has selected a lead therapeutic candidate for its PAS-003 program, a proprietary humanized monoclonal antibody (mAb) that targets α5β1 integrin, a protein found to be overexpressed in both human and mouse subjects with amyotrophic lateral sclerosis (ALS).

Key Points: 
  • Scientists at Pasithea have performed extensive mAb screening and characterization to enable selection of a lead therapeutic candidate with optimal properties for the treatment of ALS.
  • This work included further validation of α5β1 integrin as a target in both familial (SOD1) and sporadic (TDP-43) ALS mouse models with reproducible improvements on behavior and survival.
  • Extensive mechanism of action studies link disease model efficacy to effects on the migration and adhesion of immune cells.
  • Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea commented, “We have chosen the most optimal anti-α5β1 humanized mAb for the treatment of both sporadic and familial ALS.

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviv

Retrieved on: 
Tuesday, August 1, 2023
Tissue, Myelocyte, National academy, PNAS, Central nervous system, Mayo Clinic, Macrophage, Stanford University, Oregon Health & Science University, PALO, Survival, Research, SOD1, CNS, Brain cell, KTTA, Gold, HIV disease progression rates, Patient, Ras Al Khaimah Medical and Health Sciences University, Integrin, Microglia, Clinical professor, ALS, Peripheral nervous system, Pharmaceutical industry, Vaccine, Pasithea (Charites)

PALO ALTO, Calif. and MIAMI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, today announced a publication in the internationally renowned scientific peer-reviewed journal Proceedings of the National Academy of Sciences (PNAS), related to its PAS-003 drug discovery program, that describes an increased expression of α5/β1 (α5) integrin on motor neurons in ALS human and mouse tissue, as well as the blockade of this integrin as a potential new approach to treat ALS patients.

Key Points: 
  • “This work began at Stanford University, where we have spent decades studying integrin related targets,” commented Pasithea's Chairman, Dr. Larry Steinman.
  • “It was especially gratifying to see the α5 antibody survival and behavioral benefits replicated at an independent CRO.
  • These results provide novel data on the role and spatial distribution of α5 integrin in ALS and provide efficacy data of anti-α5 integrin treatment in the SOD1G93A mouse model, the gold standard preclinical ALS model.
  • We believe this treatment may be used as a monotherapy or in combination with existing standard of care in both sporadic and genetic type of ALS.

Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference

Retrieved on: 
Tuesday, December 6, 2022
Conference, Psychopharmacology, Sporadic group, Life expectancy, Multiple sclerosis, Behavior, Diagnosis, Noonan syndrome, Motor neuron, CNS, Chemistry, Heredity, National academy, Amyotrophy, ALS, FDA, Biotechnology, Death, Amyotrophic lateral sclerosis, Central nervous system, Spinal cord, Antibody, MIAMI, Alpha-5 beta-1, Neuroscience, Survival, KTTA, SOD1, Research, Neurodegeneration, Therapy, Integrin, Brain, Patient, Pharmaceutical industry

Pasithea’s discovery candidate, PAS-003, has a novel mechanism of action with the potential to improve clinical outcomes in patients with ALS.

Key Points: 
  • Pasithea’s discovery candidate, PAS-003, has a novel mechanism of action with the potential to improve clinical outcomes in patients with ALS.
  • “We’re pleased to present our data at such a prestigious annual conference that includes a keynote address by this year’s Nobel Laureate for chemistry,” commented Dr. Steinman.
  • Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders.
  • PAS-003 is monoclonal antibody targeting alpha5/beta1 integrin for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurological diseases.